Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
Crossref DOI link: https://doi.org/10.1186/s40880-016-0140-0
Published Online: 2016-09-08
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Leng, Yun
Qiu, Lugui
Hou, Jian
Zhao, Yaozhong
Zhang, Xuejun
Yang, Shifang
Xi, Hao
Huang, Zhongxia
Pan, Ling
Chen, Wenming
Funding for this research was provided by:
Beijing Sunbio Biotech Co., Ltd.
